Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jun;65(6):956–960. doi: 10.1038/bjc.1992.200

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.

O P Solheim 1, G Saeter 1, A M Finnanger 1, A E Stenwig 1
PMCID: PMC1977753  PMID: 1616870

Abstract

From 1984 to 1989, 63 patients with diffuse, malignant mesothelioma of the pleura were treated with 4-8 courses of high-dose methotrexate (HDMTX, 3 g total dose) and citrovorum factor rescue. There were 61 male and two female patients of median age 60 years. CT scan was performed before and after treatment and used for response evaluation. Of 60 patients evaluable for response, 37% showed partial or complete remission, 32% showed no change and 32% showed progressive disease. Median survival from start of treatment for all patients was 11 months, for 42 patients with the epithelial type 12 months, and for 20 patients with sarcomatous or mixed types only 5 months. Toxicity was acceptable, with only five patients (8%) terminating therapy due to toxicity. One toxic death occurred. We conclude that HDMTX is an active regimen in malignant pleural mesothelioma. The significantly shorter survival for patients with the sarcomatous or mixed subtypes indicates that further investigations on the activity of HDMTX in mesothelioma should be limited to patients with the epithelial subtype.

Full text

PDF
956

Images in this article

957Figure 2
on p.957

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Wiernik P. H. Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol. 1981 Sep;8(3):335–343. [PubMed] [Google Scholar]
  2. Alberts A. S., Falkson G., Goedhals L., Vorobiof D. A., Van der Merwe C. A. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988 Mar;6(3):527–535. doi: 10.1200/JCO.1988.6.3.527. [DOI] [PubMed] [Google Scholar]
  3. Antman K., Shemin R., Ryan L., Klegar K., Osteen R., Herman T., Lederman G., Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988 Jan;6(1):147–153. doi: 10.1200/JCO.1988.6.1.147. [DOI] [PubMed] [Google Scholar]
  4. Brenner J., Sordillo P. P., Magill G. B., Golbey R. B. Malignant mesothelioma of the pleura: review of 123 patients. Cancer. 1982 Jun 1;49(11):2431–2435. doi: 10.1002/1097-0142(19820601)49:11<2431::aid-cncr2820491134>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  5. Butchart E. G., Ashcroft T., Barnsley W. C., Holden M. P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976 Feb;31(1):15–24. doi: 10.1136/thx.31.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colbert N., Vannetzel J. M., Izrael V., Schlienger M., Milleron B., Blanchon F., Herman D., Akoun G., Roland J., Chatelet F. A prospective study of detorubicin in malignant mesothelioma. Cancer. 1985 Nov 1;56(9):2170–2174. doi: 10.1002/1097-0142(19851101)56:9<2170::aid-cncr2820560905>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  7. Dahl I. M., Laurent T. C. Concentration of hyaluronan in the serum of untreated cancer patients with special reference to patients with mesothelioma. Cancer. 1988 Jul 15;62(2):326–330. doi: 10.1002/1097-0142(19880715)62:2<326::aid-cncr2820620217>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  8. Dahl I. M., Solheim O. P., Erikstein B., Müller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer. 1989 Jul 1;64(1):68–73. doi: 10.1002/1097-0142(19890701)64:1<68::aid-cncr2820640112>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  9. Dimitrov N. V., Egner J., Balcueva E., Suhrland L. G. High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer. 1982 Oct 1;50(7):1245–1247. doi: 10.1002/1097-0142(19821001)50:7<1245::aid-cncr2820500704>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Falkson G., Alberts A. S., Falkson H. C. Malignant pleural mesothelioma treatment: the current state of the art. Cancer Treat Rev. 1988 Dec;15(4):231–242. doi: 10.1016/0305-7372(88)90023-0. [DOI] [PubMed] [Google Scholar]
  11. Law M. R., Gregor A., Hodson M. E., Bloom H. J., Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax. 1984 Apr;39(4):255–259. doi: 10.1136/thx.39.4.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mintzer D. M., Kelsen D., Frimmer D., Heelan R., Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep. 1985 Jun;69(6):711–712. [PubMed] [Google Scholar]
  13. Raghavan D., Gianoutsos P., Bishop J., Lee J., Young I., Corte P., Bye P., McCaughan B. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol. 1990 Jan;8(1):151–154. doi: 10.1200/JCO.1990.8.1.151. [DOI] [PubMed] [Google Scholar]
  14. Sørensen P. G., Bach F., Bork E., Hansen H. H. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep. 1985 Dec;69(12):1431–1432. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES